StonvexLoading…
StonvexStonvexStonvexQuiet session — no dominant driver
Research only. Labels above describe the current state of the stock using price, volume, and news data — they are not buy or sell recommendations. Stonvex is not a registered investment advisor. Past market behavior does not imply future results.
What you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-08 | $10.63 | $10.55 | -0.75% | 1.4M |
| 05-11 | $10.71 | $10.08 | -5.88% | 1.6M |
| 05-12 | $9.96 | $10.24 | +2.81% | 1.0M |
| 05-13 | $10.07 | $10.04 | -0.30% | 1.8M |
| 05-14 | $8.08 | $6.25 | -22.71% | 10.3M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
No sell-side coverage available for RGNX.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $6.39M | $170.44M | $140.10M | $110.37M |
Operating Income | $-83.36M | $-161.20M | $-103.56M | $-51.15M |
Net Income | $-90.05M | $-193.88M | $-126.73M | $-64.79M |
EPS (Diluted) | $-1.72 | $-3.76 | $-2.46 | $-1.26 |
Total Assets | $341.89M | $453.03M | $525.20M | $581.03M |
Total Liabilities | $320.81M | $350.30M | $363.75M | $367.35M |
Cash & Equivalents | $15.23M | $34.47M | $58.80M | $79.56M |
Free Cash Flow OCF − CapEx | $-77.42M | $-126.38M | $-73.58M | $-17.13M |
Shares Outstanding | 51.62M | 50.89M | 50.62M | 50.39M |
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
Fundamentals not available for RGNX.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.